Dr Emma Stanton is Chief Executive for EIT Pathogena at EIT. This is EIT’s first flagship program. This program will harness new technologies to detect, monitor, and prevent outbreaks of infectious disease globally.
From 2020 - 2024, Emma was SVP Clinical at Oxford Nanopore Technologies and Head of Oxford Nanopore Diagnostics. In this role, Emma was responsible for the overall clinical strategy bringing nanopore sequencing to clinical applications to transform healthcare globally.
During the covid-19 pandemic in 2020, Emma was Director for Supplies, Labs and Innovation as part of the British government's NHS Test and Trace response. From September 2018 to June 2020, Emma was CEO of Four Eyes Insight. Prior to this, Emma held leadership roles at Beacon Health Options including as Chief Partnership Officer for Northeast USA, Associate Chief Medical Officer for Beacon in the USA and from 2011 - 2017, Emma was Founder and CEO of Beacon in the UK.
From 2010 – 2011, Emma was a Commonwealth Fund Harkness Fellow in Health Care Policy and Practice, and from 2011-2021 was a senior associate at Harvard Business School, USA. Emma holds an executive MBA from Imperial College, London, a MRCPsych from the Royal College of Psychiatrists and a BM from Southampton University.